Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Kitazawa, Takehisa

Class:Id	Person:9678393
_displayName	Kitazawa, Takehisa
_timestamp	2020-03-19 03:08:55
created	[InstanceEdit:9678391] Shamovsky, Veronica, 2020-03-19
firstname	Takehisa
initial	T
surname	Kitazawa
(author)	[LiteratureReference:9678380] Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens [LiteratureReference:9678398] Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity [LiteratureReference:9678400] Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity [LiteratureReference:9678405] Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro [LiteratureReference:9678407] Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V [LiteratureReference:9956990] Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
[Change default viewing format]

No pathways have been reviewed or authored by Kitazawa, Takehisa (9678393)